Background. The kidney is one of the major target organs affected by systemic lupus erythematosus. Although proliferative forms of lupus nephritis (LN) occur more frequently than membranous LN (MLN), the latter appears to have a more favourable outcome. Only a few studies have reported the outcome of patients with MLN. Methods. A retrospective analysis of patients with biopsyconfirmed MLN from a single centre in South Africa treated from 1st January 2000 to 31st December 2009. Results. The mean age of the patients (n = 42) at onset of LN was 35.0 ± 12.8 years with 73.8% of the patients being of mixed ancestry (coloureds). Eleven patients (26.2%) reached the composite end point of death or end-stage renal disease or persistent doubling of serum creatinine. The overall median survival and median renal survival times were 82.3 ± 15.5 months (95% confidence interval 52.0-112.6) and 84.5 ± 15.0 months (55.1-113.8), respectively. Also, 5-year event-free survival and renal survival were 64 and 71%, respectively. On multivariate analysis, systolic blood pressure (BP) during follow-up (P = 0.029), diastolic BP during follow-up (P = 0.020) and attainment of complete remission at 6 months (P = 0.033) were factors associated with the composite end points. Although treatment with chloroquine was not significantly associated with the composite end points (P = 0.05), we found that patients who received chloroquine had better renal survival compared with those who did not (P = 0.007). Conclusions. The outcome of patients with MLN in Cape Town is poorer than for similar patients reported from other centres across the world. Better BP control may significantly influence outcome of disease in these patients.
Introduction
An estimated 25-50% of patients with systemic lupus erythematosus (SLE) will have urinary abnormalities or decline in renal function in the early course of the disease; up to 60% of adults and 80% of children of selected populations with SLE will develop renal abnormalities in the latter course of the disease [1] . Most patients with lupus nephritis (LN) will present with the proliferative form of the disease (Class II, III and IV) and only 10-15% will have membranous LN (MLN) (Class V) [2] . MLN often presents with features of the nephrotic syndrome with renal histology showing podocyte foot process effacement and subepithelial immune depositssimilar to features of idiopathic membranous nephropathy.
Several studies have shown the outcome of patients with proliferative LN with only a few reporting on the outcome of patients with MLN following treatment [3] [4] [5] [6] [7] [8] [9] [10] [11] . Outcome studies focussing on MLN have reported better short-and long-term patient and renal survival compared to similar studies in patients with proliferative forms of LN. Also, few outcome studies of MLN have reported on the effect of adjuvant therapies such as chloroquine on the outcome of patients [12] . Since there are no outcome studies for patients with MLN from sub-Saharan Africa, we therefore sought to determine the outcome of such patients treated in our centre in Cape Town.
Materials and methods

Study population
The study was approved by the University of Cape Town Human Research Ethics Committee. Records of renal biopsies performed at the renal unit in Groote Schuur Hospital from 1st January 2000 to 31st December 2009 were reviewed and patients diagnosed with MLN (and those with MLN in combination with other varieties of LN) were selected for retrospective analysis. We excluded patients with MLN who had been treated before 1st January 2000.
Data collection
We obtained the demographic, clinical and biochemical (including serological) characteristics of the patients at the time of biopsy and during subsequent follow-up visits. Data obtained at biopsy included age, gender, race, blood pressure (BP) and various laboratory data (serum creatinine, serum albumin, haemoglobin, white cell count, platelet count, serum complement levels (C3 and C4), antinuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA) and urine protein-to-creatinine ratio). The complement levels were expressed as either normal or low, while ANA and anti-dsDNA were described as positive or negative in comparison with the reference values. The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula [13] . Types of medications used for immunosuppression to induce and maintain remission were also noted. Although our unit protocol of immunosuppression was used in the treatment of most patients [1 mg/kg/day of prednisone (tapered with time), 2 mg/kg/ day of azathioprine and 750 mg/m 2 of body surface area for cyclophosphamide], only a few patients were treated with other immunosuppression such as mycophenolate or a calcineurin inhibitor. During treatment, attempts were made to gradually reduce or withdraw medications as MLN remitted. Induction therapy was restarted in cases of flares.
Definitions
Blood pressure. Patients were classified as having hypertension if systolic BP (SBP) was persistently ≥140 mmHg and/or diastolic BP (DBP) was ≥90 mmHg or if on treatment with anti-hypertensive medications [14] . The BP used for analysis was the average of all documented BPs during follow-up visits.
Remission, relapse and flare. The remission status of the patients at 6, 12 and 24 months and the last follow-up visit was documented. Patients were classified as either being in complete remission (CR), partial remission (PR) or not in remission (NR) according to the following criteria [15] :
• CR was defined as proteinuria of <0.2 g/day with stable eGFR if normal at baseline or increase in eGFR by 25% if abnormal at baseline.
• PR was defined as reduction in proteinuria (for proteinuria between 0.2 and 2.9 g) and stable eGFR if normal at baseline or increase in eGFR by 25% if abnormal at baseline.
• NR was defined as persistent proteinuria of ≥3 g/day or progressive or worsening renal impairment.
Relapse or flare of LN was defined as clinical manifestations indicating activity, namely, active urinary sediments and increasing proteinuria with or without serological reactivation in a patient who was previously in CR or PR.
Composite end point. The composite end point for the study was persistent doubling of the serum creatinine over the baseline value or endstage renal disease (ESRD) or death. For patients who reached the end point, the period of follow-up was the interval between first renal biopsy and the time the end point was reached. Survival was calculated from the time of kidney biopsy to 31st December 2009 or until death or loss to follow-up. Adverse events associated with treatment were recorded.
Histology
The renal pathology reports were processed and reviewed by the same pathologist. The histological diagnosis based on assessment of the light microscopy, immunohistochemistry and electron microscopy was recorded. The 2003 International Society of Nephrology/Renal Pathology Society (ISN/RPS) histological classification of LN was used; hence, MLN was classified as V, V + III or V + IV [16] . The Number of glomeruli in each biopsy was reported and the histological activity and chronicity indices were reported using the method previously described by Austin et al. [17] .
Statistics
The data were analysed using SPSS software (SPSS, Chicago, IL). Categorical variables were presented as percentages and continuous variables as means ± SD. Comparison between the different racial groups, gender and subclasses of MLN was performed by analysis of variance, Student's t-test or chi-square test. Estimate of survival was done using the Kaplan-Meier survival method. Renal survival with time to ESRD was assessed using Kaplan-Meier estimates and log-rank test for comparison of survival estimates between groups after censoring for loss to follow-up, non-renal deaths and study completion. Only covariates with P ≤ 0.1 in the univariate analysis were included in the multivariate model. Multivariate analysis was done using Cox proportional hazard regression analysis to assess the association between relapse-free survival and explanatory variables after censoring for loss to follow-up and completion of study. Significant P-value was taken as P < 0.05.
Results
Demographic, clinical and biochemical features at baseline
The baseline demographic, clinical and biochemical features of the patients (n = 42) are shown in . Using the ISN/RPS classification of LN, 78.6% were classified as Class V, 4.8% as Class V + III and 16.6% as Class V + IV LN. Other histological features including number of glomeruli and activity and chronicity indices are described in Table 2 .
Treatment regimen and complications associated with treatment
The treatment regimen utilized for the different subtypes of MLN for induction and maintenance therapies as well as other adjuvant drugs used during treatment are shown in Table 3 . For induction therapy, the combined treatment with prednisone and cyclophosphamide was commonly used: 37.5% (Class V), 100.0% (Class V + III) and 83.3% (Class V + IV). Patients with sub-nephrotic range proteinuria and pure Class V LN (9.4%) received no form of immunosuppression for induction and maintenance therapy but were treated conservatively with angiotensin- converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs), anti-platelet agents and lipidlowering drugs. Also, more patients received prednisone and azathioprine for maintenance therapy (53.1%-Class V and 50.0%-Class V + IV) than other drug combinations. Only 6.3 and 16.7%, respectively, in Class V and Class V + IV were treated with the combination of prednisone and cyclophosphamide during maintenance therapy. Two patients with Class V + III LN were either maintained on prednisone alone or in combination with mycophenolate mofetil (MMF). One patient with Class V + IV LN (16.7%) could only be treated with prednisone for induction therapy as she had also presented with severe sepsis and died in that admission. Chloroquine was used as adjuvant therapy in 63.3% of patients with Class V and 50.0% of Class V + IV and several patients continued to receive ACE-i/ARB.
The adverse events associated with treatment are shown in Table 4 . Septicaemia was the most frequent adverse event that occurred following treatment (30%). Other infection-related adverse events, such as tuberculosis, diarrhoea, meningitis, pyelonephritis and herpes zoster, accounted for 25% of all adverse events. Cushingoid appearances were reported in 4/20 (20%) of patients, while diabetes occurred in 2/20 (10%) of the patients.
Comparison of the demographic, clinical, biochemical and treatment factors in patients who reached or did not reach the composite end point Tables 5 and 6 show the differences observed between the patients who reached or did not reach the composite end point of death, end-stage renal failure or persistent doubling of serum creatinine during follow-up. Eleven patients (26.2%) reached the composite end point. Significant differences between patients who reached end point and those who did not reach end point were seen in SBP during follow-up (140.5 ± 11.8 versus 119.1 ± 16.3 mmHg; P = 0.002), CR at 6 months and at the last followup visit (P = 0.007 and P = 0.013, respectively), percentage of patients with low complement C3 at onset of disease (P = 0.014), eGFR at onset of MLN (P = 0.009) and percentage of patients treated with chloroquine Outcome in membranous LN(P = 0.013). Other modalities of treatment were not significantly different between the two groups. Also, there were no differences observed in the frequency of patients who had a flare or in the histological activity and chronicity indices between the two groups (Table 5 ).
Patient and renal survival analysis
The cumulative event-free and renal survival curves are shown in Figure 1 and Figure 2A -C. The overall median survival and median renal survival times were 82.3 ± 15.5 months [95% confidence interval (95% CI) 52.0-112.6] and 84.5 ± 15.0 months (55.1-113.8), respectively. Also, 5-year event-free survival and renal survival were 64 and 71%, respectively (Figures 1 and 2A ). Although treatment with chloroquine (P = 0.007) and pure MLN histological class (P = 0.011) were associated with a better renal outcome ( Figure 2B and C), they were not significantly associated with composite end points.
Regression analysis for predictors of the composite end point
On multivariate analysis, the factors observed to be associated with the composite end points are shown in Table 7 . SBP during follow-up [hazard ratio (HR) 0.28; 95% CI 0.09-0.88, P = 0.029], DBP during follow-up (HR 5.05; 95% CI 1.28-19.9, P = 0.020) and attainment of CR at 6 months (HR 0.12; 95% CI 0.01-0.40, P = 0.033) were factors associated with the composite end points. Treatment with chloroquine approached significant association with the end points (HR 0.18; 95% CI 0.03-1.00, P = 0.05).
Discussion
MLN does not occur as commonly as proliferative LN and therefore, there are not as many studies worldwide that have reported on outcome of patients with MLN [8] [9] [10] [11] . There is evidence for better outcome in patients if the renal histology shows pure MLN than if it is of the proliferative variety [18] . This study, firstly, adds to the limited data on outcome of patients with MLN, especially so from Africa where there are no existing data. Secondly, this study has shown that factors, such as BP and use of adjuvant drugs like chloroquine, may significantly impact on the outcome of patients with MLN. The use of anti-malarials in SLE and LN is increasingly being evaluated and studies have shown that patients treated with anti-malarials tend to do better in the long run than patients who do not receive anti-malarial therapy. The Canadian hydroxychloroquine study group reported in the early 1990s that patients with quiescent SLE treated with hydroxychloroquine (HCQ) were less likely to have a clinical flare-up if maintained on HCQ [19] . In the Canadian study, patients were randomly assigned to continue receiving HCQ or placebo after at least a 6-month period of therapy with HCQ. The relative risk of a clinical flareup was 2.5 times higher in patients taking placebo than those who continued with HCQ (P = 0.02) [19] . Several reports, particularly from the LUpus in MInorities: NAture versus nurture (LUMINA) study, have shown that in patients with LN, use of anti-malarials significantly reduces progression to ESRD and prolongs patient and renal survival [12, [20] [21] [22] [23] . In one of the LUMINA publications, Pons-Estel et al. [21] observed that patients treated with HCQ showed a reduced frequency of disease activity, a lower frequency of Class IV (proliferative) LN and received lower glucocorticoid doses than patients who were not treated with HCQ. Treatment with HCQ was found to be significantly associated with protection from renal damage after adjusting for confounders (P < 0.05) [21] .
Although, in this study, there was significantly better renal survival in patients treated with chloroquine than in those who did not receive chloroquine ( Figure 2C , P = 0.007), multivariate analysis did not show association between the use of chloroquine and the composite end point (HR 0.18; 95% CI 0.03-1.00, P = 0.05). Although our data subtly adds to evidence that chloroquine may play an important role in modifying the disease process in MLN and significantly contribute towards better outcome in patients, we think larger studies of patients with MLN are more likely to yield stronger evidence for its use in patients with LN.
One of the flaws often attributed to studies that have reported a favourable outcome in SLE or LN patients treated with anti-malarials is that patients with mild symptoms of SLE disease are often treated with chloroquine, while those with severe disease are more likely to be placed on more aggressive therapies [24] . In this study, as there was no difference in the distribution of patients treated with chloroquine among the subclasses of MLN, there is clearly no case of assigning patients with lower risk to the chloroquine group. However, LN was not the indication for starting patients on chloroquine in this study. Our patients who were treated with chloroquine received it mainly for the rheumatological manifestations of SLE. Hence, the association between use of chloroquine and better renal survival may not necessarily translate to a beneficial effect of the drug as the causal relationship is hard to determine. It is also possible that those patients with rheumatological manifestations (skin and joint disease) of SLE who were treated with chloroquine had less serious renal manifestation at onset. Although studies specifically designed to test the effect of chloroquine on the outcome of patients with LN are warranted, the current observed results are still important. Event-free and renal survival reported in this study are lower when compared to similar studies of patients with MLN from other parts of the world [8, 11, 25] . For instance, Mercadal et al. [11] in a multicentre study from seven Parisian hospitals in France reported 5-and 10-year renal survival to be 97 and 88%, respectively, while a similar study in 100 Chinese patients with MLN reported 5-and 10-year renal survival to be 96.1 and 92.7%, respectively [25] . The low event-free and renal survival reported in this study may be related to a combination of socio-economic factors and possibly difficulties associated with provision of renal care for all patients with ESRD in South Africa [26] . Several of our patients are indigent and live in overcrowded homes and in the face of immunosuppression are at risk of severe infections. The high frequency of reported infections related to therapy (see Table 4 ) might be related to the poor living standards. Also, as dialysis therapy is rationed in South Africa, only patients who meet the criteria set by the government are offered renal replacement therapy [26] . Patients who do not meet the criteria are often sent home to die as they cannot afford the cost of private renal replacement therapy. This might be the reason for the similarities in the median patient and renal survival seen in this study.
In this study, we also found SBP (P = 0.029) and DBP (P = 0.020) during follow-up to be associated with the end point. Several other studies have reported the importance of hypertension (SBP or DBP or both) in determining patient and renal outcome in LN [27] [28] [29] . In a cohort of 75 patients with LN treated with cyclophosphamide in Brazil, De Castro et al. [29] evaluated the combined effects of ethnicity and hypertension in the evolution of creatinine levels between Caucasians and Afro-descendants. They showed that hypertension had a significant overall effect on delta creatinine (P = 0.015) and that the effect was more intense among Afro-descendants than among Caucasians (P = 0.027). They therefore concluded that lupus patients experience the worst prognosis of renal function probably due to the effect of hypertension and not ethnicity [29] .
We have also previously shown that SBP during follow-up was one of the important determinants of poor renal outcomes (P = 0.016) [6] . Therefore, although raised BP is not a common feature of MLN, adequate BP control may positively impact on the long-term outcome of patients. About 90% of patients in our study were treated with an ACE-i or an ARB (Tables 3 and 6 ). Such therapy, although mainly used for their anti-proteinuric actions, have also been shown to be effective at reducing BP in patients with LN [30] .
The complications found to be associated with therapy included sepsis (30%), Cushingoid appearance (20%), steroid-induced diabetes (10%), avascular necrosis of the femoral head (5%) and amenorrhoea (5%). Other infection-related complications, such as tuberculosis, meningitis, herpes zoster, diarrhoea and pyelonephritis, accounted for another 25% of complications related to therapy. The use of cyclophosphamide and azathioprine for induction and maintenance therapy, respectively, have been shown to be associated with these side effects in patients with LN [3] . Chan et al. [3] observed a higher frequency of the occurrence of infections, amenorrhoea, alopecia and leucopenia in patients treated with cyclophosphamide and azathioprine than in those who were treated with MMF. Such high rates of all infections in our study suggests the need for a review of our current immunosuppression protocol and the need for frequent and regular patient monitoring. Our study also confirms the value of remission in patients with MLN. Specifically, we showed that there were more patients in CR at 6 months and last follow-up visit in the group that did not reach the composite end point than in the group that reached the composite end point. Chen et al. [31] have shown that patients with LN reaching CR have better 10-year patient and renal survival than those with partial or no remission with or without ESRD.
The limitations of this study include the retrospective collection of data that made it difficult for us to establish certain socio-demographic and clinical variables of the patients, which were undocumented at the time when the patients were initially assessed. We were thus unable to evaluate the extent to which socio-demographic factors may have contributed to the outcomes of these patients with MLN. Another limitation is that associated with assigning patients to the chloroquine group if they had continuously been treated with chloroquine at any time during the follow-up period. This may have caused an immortal person-time bias which we are unable to control for given the retrospective design of this study. However, as many other studies have similarly shown better outcomes in patients treated with chloroquine than in those not receiving chloroquine, we feel confident about the outcomes reported in this study. Finally, although our sample size is comparable to other outcome studies of patients with MLN, the small sample size may be an obvious limitation.
Conclusion
The overall outcome of patients with MLN in Cape Town is poorer than for similar patients reported from other centres across the world. Although use of chloroquine and SBP are some factors that predict outcome, there is need to review our immunosuppressive protocol for patients with MLN given the high frequency of patients with infections. Prospectively designed studies are required to assess adequately the long-term outcomes of patients with MLN in Cape Town.
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